CD44 and neoplasm: FKBPL and its peptide derivatives have previously shown potent anti-angiogenic activity resulting in a tumour growth delay in a range of xenografts studies, potentially through the cell surface receptor CD44.20,22,24 However, for the first time, we observed no tumour growth delay in the OVCAR3 xenografts after treatment with ALM201 (Fig. 3b).